Multiple Myeloma

Intravenous immunoglobulin could potentially be given throughout the duration of anti-BCMA bispecific antibody therapy for the treatment of multiple myeloma.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.

Mezigdomide boosted T cell activity and worked in patients with multiple myeloma who were resistant to prior therapeutic agents.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Key opinion leaders provide insight on patient considerations when formulating an optimal treatment regimen for multiple myeloma.

Drs Haumschild, Anderson, and Hinojosa explore current MM treatment pathways.

Medical experts discuss treatment options for indolent and aggressive relapse multiple myeloma.

Dr Haumschild opens the discussion with Larry Anderson, MD, PhD, and Gabe Hinojosa, PharmD, BCOP, regarding various states of relapse in multiple myeloma.

Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.

A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.

Multiple myeloma treatment selection is critical due to the potential for developing treatment resistance over time to the currently prescribed drugs.

Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.

In their closing thoughts, Mr Haumschild leads the panel in a discussion regarding treatments on the horizon for patients with relapsed/refractory multiple myeloma.

Toxicity management associated with anti-CD38 drugs is highlighted by a panel of medical experts.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

Total cost of care for multiple myeloma can be significantly affected by selection of dosing regimen.

Key opinion leaders emphasize the critical role of effective clinical pathways for treatment in multiple myeloma.